Director Ronald E. Bruehlman of GoodRx Holdings, Inc. filed a Form 4 on November 9, 2026, reporting the vesting of 21,692 deferred stock units into Class A Common Stock on November 8, 2026.

Key Highlights

  • Reporting person: Ronald E. Bruehlman, a Director of GoodRx Holdings, Inc. (NASDAQ:GDRX)
  • Transaction: 21,692 deferred stock units (DSUs) converted to Class A Common Stock via transaction code M on November 8, 2026
  • Price of derivative security: $0, as reported in the filing
  • Resulting ownership: 229,044 shares of Class A Common Stock directly owned following the transaction
  • Remaining DSUs: 21,692 deferred stock units remain beneficially owned following the reported transaction
  • Settlement trigger: DSUs will settle on the earliest of December 31, 2029, separation from service, a change in control, death, or disability

Bruehlman DSU Vesting Details and Post-Transaction Ownership at GoodRx

According to the Form 4 filed with the SEC on November 9, 2026, Ronald E. Bruehlman, a director of GoodRx Holdings, Inc., reported the vesting of a portion of a deferred stock unit award. The filing states that the DSU award vested "as to one-third of the shares underlying the award on November 8, 2026," converting 21,692 units into 21,692 shares of Class A Common Stock via an M-coded transaction.

The filing discloses that following the transaction, Bruehlman directly holds 229,044 shares of Class A Common Stock. In Table II, the filing shows that 21,692 deferred stock units remain outstanding under his direct ownership. Each deferred stock unit represents, according to the filing, "a contingent right to receive one share of Class A common stock." The price of the derivative security is listed as $0.

The filing further explains that the remaining deferred stock units "will settle on the earliest to occur of the following events: (i) December 31, 2029; (ii) Separation from Service; (iii) a Change in Control; (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors)." The Form 4 was signed by Gracye Cheng as Attorney-in-Fact for Ronald E. Bruehlman on November 9, 2026.

What Was Disclosed

GoodRx Holdings, Inc. director Ronald E. Bruehlman reported the vesting of 21,692 deferred stock units into Class A Common Stock on November 8, 2026, bringing his direct share ownership to 229,044 shares, with 21,692 DSUs remaining outstanding.